Quantcast

Industry news that matters to you.  Learn more

BrainScope Announces Publication Describing Proprietary Concussion Biomarker to Assess Potential Severity and Predict Prolonged Recovery

BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, recently announced that researchers have published preliminary results related to a multi-modal concussion assessment capability for potential severity and likelihood of prolonged recovery from concussions.  Published in the peer-reviewed journal Computers in Biology and Medicine, the paper entitled, “A multimodal biomarker for concussion identification, prognosis and management” describes a study which enrolled 568 concussed and matched control patients between the ages of 13-25 from 29 colleges and 19 high schools. Subjects were tested at the time of injury and at multiple time points during recovery.

New Study Shows GFAP and UCH-L1 are not Useful Biomarkers for Diagnosing Mild Traumatic Brain Injury

In patients who suffered acute orthopedic injuries, two proposed biomarkers for mild traumatic brain injury (mTBI) were not able to distinguish between patients who did or did not have mTBI. Relying on elevated levels of the proteins GFAP and UCH-L1 to identify patients with mTBI could lead to false-positive diagnoses and unnecessary brain imaging, as reported in an article in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Neurotrauma website until March 7, 2017.